poster

52-Week Open-Label Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Centanafadine (CTN) is a novel norepinephrine/dopamine/serotonin reuptake inhibitor in development for attention-deficit/hyperactivity disorder (ADHD). Long-term (52 weeks) safety and exp...

10/26/2023

A case of acute intermittent porphyria attack with psychiatric symptoms in a female resolving with the removal of stressors and lack of medical treatment

This poster addresses a case of a middle-aged female with known acute intermittent porphyria and substance use disorder presenting with psychotic symptoms. During her hospitalization, she...

10/26/2023

Safety and Efficacy of KarXT (Xanomeline–Trospium) in Patients With Schizophrenia: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (EMERGENT-2)

Abstract: Background: In the 5-week, randomized, double-blind, placebo-controlled, phase 2 EMERGENT-1 study (NCT03697252), the M1/M4 preferring muscarinic receptor agonist KarXT met prima...

01/26/2023

TAAR1 Agonist Ulotaront Improves Glycemic Control and Reduces Body Weight in Rodent Models of Diabetes, Obesity, and Iatrogenic Weight Gain

Abstract: Introduction: Here we summarize preclinical results assessing the effects of ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist under investigation for the treatment...

01/25/2023

Review of the TAAR1 Agonist Ulotaront: Part I - From Discovery to Clinic

Abstract: Introduction: Here we provide a brief review of the discovery of ulotaront and preclinical research suggesting efficacy in schizophrenia, leading to the first clinical trial of ...

01/25/2023

Review of the trace amine-associated receptor 1 (TAAR1) agonist ulotaront: Part II - summary of initial clinical efficacy/safety results

Abstract: Introduction: Here we summarize ongoing clinical research characterizing the efficacy and safety of ulotaront as a member of the novel trace amine-associated receptor 1 (TAAR1) ...

01/25/2023

Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion

Abstract: Introduction: Solriamfetol is a wake-promoting agent (WPA) approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The...

01/25/2023

Depression and Anxiety in Medical Students during the 2020 COVID-19 Pandemic

Abstract: Medical students are prone to anxiety and depression, largely due to the nature of their coursework. During the COVID-19 pandemic, many medical students were required to study f...

01/19/2023

Healthcare Provider Perspective of Benztropine Use in Drug-Induced Movement Disorders, Including Tardive Dyskinesia, a 2021 - 2022 Real-World Survey

Abstract: Introduction: Drug-induced movement disorders (DIMDs), including tardive dyskinesia (TD), are commonly associated with dopamine receptor-blocking medications. Benztropine is be...

01/19/2023

Challenging Perceived Barriers to Digital Therapeutic Treatment Among Patients with Experiential Negative Symptoms of Schizophrenia

Introduction Experiential negative symptoms (ENS) are a major schizophrenia associated burden. Perceptions about the inability of people with schizophrenia to use technology are a barrier...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products